No abstract

A minority of GPs admit to frequently overriding their drug interaction alert systems without properly checking them. The type of computer system used by GPs may make it more or less likely that they override alerts.

Background The U.S. Office for Human Research Protections has proposed that end points of randomized trials comparing the effectiveness of standard medical practices are risks of research that would require disclosure and written informed consent, but data are lacking on the views of potential participants. Objective To assess attitudes of U.S. adults about risks and preferences for notification and consent for research on medical practices. Design Cross-sectional survey conducted in August 2014. Setting Web-based questionnaire. Patients 1095 U.S. adults sampled from an online panel (n = 805) and an online convenience river sample (n = 290). Measurements Attitudes toward risk, informed consent, and willingness to participate in 3 research scenarios involving medical record review and randomization of usual medical practices. Results 97% of respondents agreed that health systems should evaluate standard treatments. Most wanted to be asked for permission to participate in each of 3 scenarios (range, 75.2% to 80.4%), even if it involved only medical record review, but most would accept nonwritten (oral) permission or general notification if obtaining written permission would make the research too difficult to conduct (range, 70.2% to 82.7%). Most perceived additional risk from each scenario (range, 64.0% to 81.6%). Limitation Use of hypothetical scenarios and a nonprobability sample that was not fully representative of the U.S. population. Conclusion Most respondents preferred to be asked for permission to participate in observational and randomized research evaluating usual medical practices, but they are willing to accept less elaborate approaches than written consent if research would otherwise be impracticable. These attitudes are not aligned with proposed regulatory guidance. Primary Funding Source National Center for Advancing Translational Sciences at the National Institutes of Health.